EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

EMA head of orphan medicines Kristina Larsson presenting virtually at the RAPS Euro Convergence 2025
EMA head of orphan medicines Kristina Larsson presenting virtually at the RAPS Euro Convergence 2025 (Pink Sheet)

More from RAPS

More from Conferences